Ipsen decides to retain the Dreux-based primary care industrial facility within the Group's scope

Ipsen decides to retain the Dreux-based primary care industrial
facility within the Group's scope


Paris (France), 11 July 2012 - Ipsen  today announced its decision to retain the Dreux (France)-based industrial facility within the scope of its activity. Considering the
perspectives of Ipsen's primary care activity internationally and as a result the higher thanexpected production volumes at this site since the beginning of this year, the Group has decided to keep its Dreux industrial site.

Industrial activities and employment will be maintained at the site in the light of these revised forecasts.

Ipsen Chairman and CEO, Marc de Garidel stated, "I am delighted to announce this decision in a context of the positive evolution for our international primary care activities. I am extremely confident in the determination and ability of our teams to forge a new future for the Dreux industrial site."

Ipsen's sites in Dreux 
As part of the Group's new primary care strategy made public in June 2011, Ipsen had been seeking a buyer for the industrial site in response to the expected decline in volumes – in particular in the French market. In the light of recent developments, this assumption is no longer valid. Ipsen employs more than 580 people at its sites in Dreux, including 350 people in production and distribution. The different sites include:

- a production facility producing in excess of one billion sachets, 700 million tablets, 235 million dry powder capsules and 65 million packs per year
- a distribution center handling 10,000 tons of drugs and 80 million boxes of drugs in transit to more than 80 countries each year
- a pharmaceutical development unit
-  French payroll administration
-  the Group IT Department

About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011.  Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of
partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500 employees. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and  eligible to the "Service de Règlement Différé"
("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.       

Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Group's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. 
Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which  may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from Generics that might translate into loose of market shares. 

Furthermore, the Research and Development process  involves several stages each of which involve the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to  demonstrate the safe and effective nature of the product
concerned. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave  in such ways which could cause damage to the Group's activities and financial results. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such
statements are based, unless so required by applicable law. 

The Group's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.

For further information:
Media
Didier Véron
Vice President, Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16 
Fax: +33 (0)1 58 33 50 58
E-mail: [email protected]

Financial Community
Pierre Kemula Stéphane Durant des Aulnois
Vice President, Investor Relations 
Tel.: +33 (0)1 58 33 60 08 
Fax: +33 (0)1 58 33 50 63
E-mail: [email protected]
Tel.: +33 (0)1 58 33 60 09 
Fax: +33 (0)1 58 33 50 63
E-mail: [email protected]

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.